[Doxifluridine for treatment of colorectal cancer].
Nishimura
Genichi
G
Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University.
Miwa
Koichi
K
D000964:Antimetabolites, Antineoplastic / Q000378:metabolism* / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D005467:Floxuridine / Q000378:metabolism* / Q000627:therapeutic use*; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D010430:Pentosyltransferases / Q000378:metabolism; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use; D011379:Prognosis; D057845:Pyrimidine Phosphorylases; D013939:Thymidine Phosphorylase / Q000378:metabolism
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D005467:Floxuridine; D003841:Deoxycytidine; D000069287:Capecitabine; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; D013939:Thymidine Phosphorylase; D005472:Fluorouracil; C025034:doxifluridine